Strata Critical Medical, Inc. (SRTA) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	280.8M	197.1M	248.7M	225.2M	146.1M
Cost of Revenue	222.9M	156.0M	189.8M	183.1M	123.8M
Gross Profit	57.8M	41.1M	58.9M	42.1M	22.3M
Operating Expenses
R&D Expense	—	3.1M	3.2M	4.6M	5.5M
SG&A Expense	56.8M	60.9M	89.7M	105.6M	70.3M
General & Admin Expense	8.8M	—	81.7M	95.2M	62.5M
Selling & Marketing Expense	367.0K	—	8.0M	10.4M	7.7M
Other Expenses	19.7M	(448.0K)	—	—	—
Total Operating Expenses	76.4M	63.5M	92.8M	110.2M	75.8M
Cost and Expenses	299.4M	219.5M	282.6M	293.3M	199.6M
Operating Income (EBIT)	(18.6M)	(22.4M)	(33.9M)	(68.1M)	(53.5M)
Non-Operating
Interest Income	1.4M	4.2M	7.2M	8.4M	3.4M
Interest Expense	—	—	—	—	—
Net Interest Income	1.4M	4.2M	7.2M	8.4M	3.4M
Other Non-Op Income/Expense	(2.5M)	2.3M	6.4M	10.6M	25.5M
Non-Operating Income (excl Interest)	1.2M	(9.7M)	(6.4M)	(10.6M)	(25.5M)
EBT (Pre-Tax Income)	(21.1M)	(20.1M)	(27.6M)	(57.5M)	(28.0M)
Income Tax Expense	—	—	(255.0K)	(1.5M)	(772.0K)
Bottom Line
Net Income	(24.8M)	41.3M	(27.3M)	(56.1M)	(27.3M)
Earnings from Cont. Ops	(21.1M)	(20.1M)	(27.3M)	(56.1M)	(27.3M)
Earnings from Discont. Ops	(3.7M)	61.4M	—	—	—
Bottom Line Net Income	(24.8M)	41.3M	(27.3M)	(56.1M)	(27.3M)
Per Share
Basic EPS	($0.29)	$0.50	($0.35)	($0.76)	($0.38)
Diluted EPS	($0.29)	$0.50	($0.35)	($0.76)	($0.38)
Revenue Per Share	$3.18	$2.39	$3.21	$3.06	$2.05
Shares
Basic Shares Outstanding	88.3M	82.5M	77.5M	73.5M	71.2M
Diluted Shares Outstanding	88.3M	82.5M	77.5M	73.5M	71.2M
Profitability Metrics
EBITDA	(5.2M)	(5.7M)	(21.6M)	(50.4M)	(22.3M)
D&A	14.6M	6.9M	6.0M	7.1M	5.7M
EBIT	(16.0M)	(12.6M)	(27.6M)	(57.5M)	(28.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026